A DNA test could help match patients with psychiatric medications, potentially reducing the long and frustrating ...

In 2022, Arizona was one of the first states in the nation to pass legislation (House Bill 2144) requiring Medicaid and commercial insurance plans to cover qualified biomarker tes ...

I would love to help you with your mental health needs. I am licensed and dually board certified both as a Family Nurse Practitioner and a Psychiatric/Mental Health Nurse Practitioner. I have worked ...

As a Physician Assistant at Bionic Bloom Wellness Collective, I bring a compassionate and integrative approach to mental health care, combining evidence-based medical practices with the transformative ...

Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year ...

Four out of five adults in Florida who need addiction treatment go without care. The Haven Detox - Florida urges people ...

Fourth Quarter Revenue: $210 million, above the high end of the pre-announced range. Full Year 2025 Revenue: $824.5 million. Fourth Quarter Test Volume: 382,000 test results delivered. myRisk Oncology ...

Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

Myriad Genetics Inc. (NASDAQ:MYGN) presented fourth quarter and full year 2025 results on February 23, 2026, showcasing improved operational execution and profitability despite a challenging year that ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, ...